ILC2s and inhibits type 1 immunity against multiple myeloma. These results argue against therapeutic administration of IL-33 to myeloma patients.
Authors | Guillerey, Camille; Stannard, Kimberley; Chen, Jason; Krumeich, Sophie; Miles, Kim; Nakamura, Kyohei; Smith, Jessica; Yu, Yuan; Ng, Susanna; Harjunpää, Heidi; Teng, Michele W L; Engwerda, Christian; Belz, Gabrielle T; Smyth, Mark J |
---|---|
Journal | IMMUNOLOGY AND CELL BIOLOGY |
Pages | 65-83 |
Volume | 99 |
Date | 1/08/2020 |
Grant ID | 1122183 |
Funding Body | Cancer Australia |
URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1111/imcb.12390 |
Download Article |